459 episodes
Pareto Securities Healthcare Conference: Sedana Medical's inhaled sedative drug/device combo is currently in front of FDA - they hope to change the ICU with it
09/02/2026 | 7 mins.CEO Johannes Doll describes what he believes are the advantages of an inhaled sedative vs the traditional IV. The company already has experience commercializing this in Europe, with 1 out of 7 ICU patients in Germany currently using it. The U.S. PDUFA date is April 16.Pareto Securities Healthcare Conference: Pareto's Dan Akschuti highlights the innovation coming out of the Nordics region and companies that have filings in front of FDA
09/02/2026 | 5 mins.He says that capital is returning to the sector and that investors have been doing more scientific due diligence recenetly. Plus, the impact of AI on biotech.Congressman Jake Auchincloss discusses the economic impact of biotech, global competition, and efforts he is taking to solidify funding, modernize regulation, and keep the United States on top
09/02/2026 | 33 mins.Interviewed by MassBio CEO Kendalle Burlin O'Connell, Congressman Auchincloss of Massachusetts describes the impact he believes a tightening of funding for basic research is having on our industry and measures he would take to bolster innovative research. He advocates for making it easier to run early stage clinical trials in the U.S. and for it to be less costly for small biotech companies to engage with FDA.Pareto Securities Healthcare Conference: BioInvent believes that it has found the next big checkpoint in TNFR2 - this summer they had data both in solid and liquid tumors
09/02/2026 | 7 mins.CEO Martin Welschof walks us through recent ASCO (ovarian in combo with Keytruda) and EHA (CTLC) data for BI-1808, and describes why the company believes TNFR2 is a compelling checkpoint with wide applicability. Plus, BI-1206 (FcyRIIB), which will have NCSLC data later this year and BioInvent ultimately hopes to partner.Pareto Securities Healthcare Conference: Orexo believes that nasal delivery is superior to other modalities for most uses - they plan to file their naloxone program with FDA immanently
09/02/2026 | 12 mins.CEO Nikolaj Sørensen walks us through all the potential benefits of delivering medicines via a nasal spray, would theoretically could even include the ability to cross the BBB for CNS conditions. Naloxone and epinephrine are the most advance, and Orexo also has plans for a nasal spray GLP and vaccines.
Sidenote by AsapSCIENCEComedy, Life Sciences, Science
Stuff To Blow Your MindLife Sciences, Science
Health Optimization Medicine PodcastAlternative Health, Health & Wellness, Life Sciences, Science
Speaking of PsychologyHealth & Wellness, Life Sciences, Mental Health, Science
The Joy of WhyLife Sciences, Science
Science of Perception BoxHealth & Wellness, Life Sciences, Mental Health, Science
Science FridayEarth Sciences, Life Sciences, Natural Sciences, Science
Short WaveDaily News, Life Sciences, News, Science
UnexplainableLife Sciences, Science
Listen to BiotechTV - News, Sidenote by AsapSCIENCE and many other podcasts from around the world with the radio.net app
Get the free radio.net app
- Stations and podcasts to bookmark
- Stream via Wi-Fi or Bluetooth
- Supports Carplay & Android Auto
- Many other app features
Get the free radio.net app
- Stations and podcasts to bookmark
- Stream via Wi-Fi or Bluetooth
- Supports Carplay & Android Auto
- Many other app features
BiotechTV - News
download the app,
start listening.
USA